peoplePerson
Justin F. Gainor
Showed that oncogene-driven lung cancers respond poorly to immunotherapy and led the pivotal RET and ALK inhibitor studies.
Led the ARROW pralsetinib study and key analyses of ALK resistance and of PD-1 blockade in EGFR/ALK-positive lung cancer; directs thoracic cancers at MGH.
Role
Director, Center for Thoracic Cancers
Institution
Specialisms
ALK and ROS1 lung cancerImmunotherapy in oncogene-driven NSCLCRET
Profiles
| Title | Journal | Year |
|---|---|---|
| Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW) | Lancet Oncology | 2021 |
| EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer | Clinical Cancer Research | 2016 |